Analgin (metamizole sodium) tablets 0.5 №10

active ingredient: 1 tablet contains metamizole sodium monohydrate 500 mg;

excipients: potato starch, calcium stearate.

Pills.

Basic physical and chemical properties: tablets of white or white color with a yellowish tint, flat-cylindrical shape, with a chamfer and a line.

Analgesics and antipyretics. ATX code N02B B02.

A pyrazolone derivative, a cyclooxygenase blocker. Reduces the formation of prostaglandins from arachidonic acid. It differs from other cyclooxygenase blockers in a slightly pronounced anti-inflammatory effect with a pronounced analgesic, antipyretic and antispasmodic effect. The antispasmodic effect is manifested on the smooth muscles of the urinary and biliary tract.

It prevents the conduction of painful extra- and proprioceptive impulses along the Gaulle and Burdach bundles, increases the excitability threshold of the thalamic centers of pain sensitivity, and increases heat transfer.

Rapidly absorbed from the gastrointestinal tract. In the intestinal wall, it is hydrolyzed to form an active metabolite. It is absent in the blood unchanged. The active metabolite is 50-60% bound to plasma proteins. The time to reach maximum plasma concentration is 1-2 hours. The half-life is 2.5 hours. Excreted by the kidneys.

Pain syndrome of various origins: headache, toothache, neuralgia, sciatica, pain in muscles, joints, pain during menstruation. As an aid to reduce pain after surgical and diagnostic interventions. Hyperthermic syndrome in infectious and inflammatory diseases.

Hypersensitivity to the components of Analgin (metamizole sodium) tablets 0.5, pyrazolone derivatives. Changes in the composition of peripheral blood: agranulocytosis, leukopenia. Blood diseases: anemia of any etiology, cytostatic or infectious neutropenia. Pronounced changes in the function of the liver and kidneys (porphyrin metabolism). Congenital deficiency of glucose-6-phosphate dehydrogenase. Bronchial asthma. Suspicion of acute surgical pathology.